If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Holding(s) in Company

15 Jan 2010 07:00

RNS Number : 6020F
Synairgen plc
15 January 2010
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Synairgen plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

F&C Asset Management plc

4. Full name of shareholder(s) (if different from 3.):

See box 9 below

5. Date of the transaction and date on which the threshold is crossed or reached:

13/01/2010

6. Date on which issuer notified:

14/01/2010

7. Threshold(s) that is/are crossed or reached:

10%

8. Notified details:

A: Voting rights attached to shares

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

GB00B0381Z20 GBP 0.01

7,318,600

7,318,600

5,718,600

-

5,718,600

-

9.57%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/  Conversion  Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 -

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise  price

Expiration  date

Exercise/ Conversion  period

Number of voting  rights instrument  refers to

% of voting rights

 -

 

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

5,718,600

9.57%

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:

F&C Asset Management plc - Client : 

No. of voting rights

% of total voting rights

Registration name

F&C Investment Funds ICVC: UK Equity Fund

3,447,535

5.77%

Chase Nominees Limited

Other client holdings are below 3%

Proxy Voting:

10. Name of proxy holder:

F&C Asset Management plc

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14 Contact name:

Mike Bassi, F&C Asset Management plc

15. Contact telephone name:

0131 718 1093

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFSALLISLII
Date   Source Headline
9th Apr 20257:00 amRNSCancellation - Synairgen plc
3rd Apr 20257:00 amRNSUpdate on trading post cancellation
28th Mar 20252:21 pmRNSResult of General Meeting
11th Mar 20257:00 amRNSProposed cancellation of trading on AIM
17th Jan 202512:55 pmRNSHolding(s) in Company
16th Jan 20253:42 pmRNSMartin Murphy appointed as Non-Executive Director
16th Jan 20253:42 pmRNSResult of General Meeting and Total Voting Rights
15th Jan 20255:37 pmRNS£18m raised to fund Phase 2 INVENT clinical trial
20th Dec 20247:00 amRNSProposed Fundraising
30th Oct 20246:09 pmRNSExercise of Share Options and Total Voting Rights
10th Oct 20245:05 pmRNSResults of AGM and Appointment of New Chairman
26th Sep 20247:00 amRNSInterim Results
18th Sep 20247:00 amRNSAppointment of New Chairman and Notice of AGM
5th Sep 20247:00 amRNSBoard Change
27th Jun 20247:00 amRNS2023 Full Year Results
15th Nov 20237:00 amRNSGrant of Options
11th Oct 20237:00 amRNSAppointment of New Chief Financial Officer
3rd Oct 20237:00 amRNSAppointment of Chief Medical Officer
21st Sep 20237:00 amRNSInterim Results
29th Jun 20236:02 pmRNSResult of AGM
29th Jun 202310:00 amRNSAnnual General Meeting Presentation
22nd Jun 20237:00 amRNSGrant of Options
23rd May 20237:00 amRNSPosting of Annual Report and Notice of AGM
27th Apr 20237:00 amRNS2022 Full Year Results
17th Apr 20237:00 amRNSNotice of Full Year results
13th Mar 20234:40 pmRNSSecond Price Monitoring Extn
13th Mar 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 202211:30 amRNSSPRINTER Trial Results Published
14th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSBoard Changes
7th Nov 20224:40 pmRNSSecond Price Monitoring Extn
7th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
3rd Nov 20224:35 pmRNSPrice Monitoring Extension
20th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20221:35 pmRNSHolding(s) in Company
4th Oct 20227:02 amRNSData from the US NIH-led ACTIV-2 Phase 2 trial
29th Sep 20227:01 amRNSBoard Changes
29th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSSPRINTER Long COVID data presented at IDWeek
15th Sep 20227:00 amRNSNotice of Interim Results
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSPositive Findings from SG015 Tri-al Analysis
5th Sep 20227:00 amRNSCompany Announce Collaboration on UNIVERSAL Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.